Marian Fedor1, M Samoš2, R Šimonová3, J Fedorová4, I Škorňová3, L Duraj3, J Staško3, F Kovář2, M Mokáň2, P Kubisz3. 1. Clinic of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia mfedor@unm.sk. 2. Clinic of Internal Medicine I., Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia. 3. Clinic of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia. 4. Hemo-Medika s.r.o., Centre of Hemostasis and Thrombosis, Martin, Slovakia.
Abstract
INTRODUCTION: Dual antiplatelet treatment (DAPT) with clopidogrel and aspirin represents common approach in prevention of thromboembolic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). The drawback of clopidogrel treatment is large interindividual variability in response. AIM: Our article aims to suggesting the most convenient method in monitoring the DAPT of post-PCI patients. METHODS: We analyzed the on-treatment platelet reactivity by light transmission aggregometry and vasodilator-stimulated phosphoprotein (VASP) flow cytometric assay. Samples were obtained in 3 intervals: first prior to PCI, then 1, and 30 days after PCI. RESULTS: Based on VASP-platelet reactivity index (PRI), we observed 100% response rate in prasugrel-treated patients and 62% to 73 % in the clopidogrel group. Overall, only 2 (7%) patients with the VASP-PRI value in therapeutic range had major adverse cardiovascular events. CONCLUSION: Our results hint VASP-phosphorylation assay as a relevant method for guiding and tailoring DAPT.
INTRODUCTION: Dual antiplatelet treatment (DAPT) with clopidogrel and aspirin represents common approach in prevention of thromboembolic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). The drawback of clopidogrel treatment is large interindividual variability in response. AIM: Our article aims to suggesting the most convenient method in monitoring the DAPT of post-PCI patients. METHODS: We analyzed the on-treatment platelet reactivity by light transmission aggregometry and vasodilator-stimulated phosphoprotein (VASP) flow cytometric assay. Samples were obtained in 3 intervals: first prior to PCI, then 1, and 30 days after PCI. RESULTS: Based on VASP-platelet reactivity index (PRI), we observed 100% response rate in prasugrel-treated patients and 62% to 73 % in the clopidogrel group. Overall, only 2 (7%) patients with the VASP-PRI value in therapeutic range had major adverse cardiovascular events. CONCLUSION: Our results hint VASP-phosphorylation assay as a relevant method for guiding and tailoring DAPT.
Authors: Matej Samoš; Marián Fedor; František Kovář; Peter Galajda; Tomáš Bolek; Lucia Stančiaková; Jana Fedorová; Ján Staško; Peter Kubisz; Marián Mokáň Journal: J Diabetes Res Date: 2016-07-17 Impact factor: 4.011
Authors: Matej Samoš; Lucia Stančiaková; Lukáš Duraj; František Kovář; Marián Fedor; Radoslava Šimonová; Tomáš Bolek; Peter Galajda; Ján Staško; Peter Kubisz; Marián Mokáň Journal: Medicine (Baltimore) Date: 2017-02 Impact factor: 1.889
Authors: Matej Samoš; Ingrid Škorňová; Tomáš Bolek; Lucia Stančiaková; Barbora Korpallová; Peter Galajda; Ján Staško; Peter Kubisz; Marián Mokáň Journal: Diagnostics (Basel) Date: 2021-01-19
Authors: Matej Samoš; Marián Fedor; František Kovář; Michal Mokáň; Tomáš Bolek; Peter Galajda; Peter Kubisz; Marián Mokáň Journal: J Diabetes Res Date: 2015-12-28 Impact factor: 4.011